NASDAQ · PRQR
Healthcare · Biotechnology
$1.86
Up+$0.02 (+0.81%)
Updated Aug 13, 2026, 5:18 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PRQR closed at $1.86 after 21 trading sessions, up 5.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $1.91 | $1.9399 | $1.86 | $1.86 | 422.4K |
| Aug 11, 2026 | $1.82 | $1.94 | $1.79 | $1.92 | 585.7K |
| Aug 10, 2026 | $1.85 | $1.88 | $1.80 | $1.81 | 515.74K |
| Aug 7, 2026 | $1.92 | $1.97 | $1.87 | $1.875 | 558.95K |
| Aug 6, 2026 | $1.98 | $2.00 | $1.88 | $1.90 | 1.25M |
| Aug 5, 2026 | $1.88 | $1.98 | $1.85 | $1.97 | 1.31M |
| Aug 4, 2026 | $1.80 | $1.86 | $1.74 | $1.83 | 1.25M |
| Aug 3, 2026 | $1.73 | $1.7599 | $1.68 | $1.71 | 558.96K |
| Jul 31, 2026 | $1.79 | $1.79 | $1.70 | $1.72 | 1.02M |
| Jul 30, 2026 | $1.74 | $1.81 | $1.735 | $1.78 | 586.29K |
| Jul 29, 2026 | $1.76 | $1.80 | $1.71 | $1.73 | 326.94K |
| Jul 28, 2026 | $1.73 | $1.76 | $1.66 | $1.76 | 495.13K |
| Jul 27, 2026 | $1.78 | $1.78 | $1.71 | $1.73 | 683.1K |
| Jul 24, 2026 | $1.79 | $1.84 | $1.70 | $1.72 | 567.93K |
| Jul 23, 2026 | $1.81 | $1.83 | $1.74 | $1.79 | 590.12K |
| Jul 22, 2026 | $1.87 | $1.90 | $1.79 | $1.81 | 824.68K |
| Jul 21, 2026 | $1.825 | $1.995 | $1.81 | $1.88 | 2.23M |
| Jul 20, 2026 | $1.70 | $1.785 | $1.695 | $1.76 | 1.17M |
| Jul 17, 2026 | $1.67 | $1.76 | $1.62 | $1.70 | 676.77K |
| Jul 16, 2026 | $1.77 | $1.77 | $1.67 | $1.67 | 601.85K |
| Jul 15, 2026 | $1.72 | $1.79 | $1.68 | $1.77 | 447.99K |
The latest Smart Investors Daily articles mentioning PRQR.
PRQR research
Company profile and research snapshot.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 29, 2026 | Evercore ISI Group | Outperform | — |
| Jun 26, 2026 | Jones Trading | Buy | — |
| Jun 26, 2026 | Chardan Capital | Buy | — |
| Apr 9, 2026 | Chardan Capital | Buy | — |
| Nov 4, 2025 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 3, 2026
https://www.sec.gov/Archives/edgar/data/1612940/000110465926089780/xslF345X06/tm2622051-1_4seq1.xml
Benzinga · Jul 6, 2026
https://www.sec.gov/Archives/edgar/data/1612940/000110465926080750/tm2619566-1_f3.htm
SeekingAlpha · Jul 4, 2026
ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with...
Benzinga · Jun 29, 2026
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRQR.
